Merck 2Q Revenues: $6.1 billion (-1%) 2Q Earnings: $1.8 billion (+5%) YTD Revenues: $11.9 billion (flat) YTD Earnings: $5.1 billion (+50%) Comments: Worldwide sales of Singulair were $1.1 billion in the quarter (-1%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.2 billion (-9%). Worldwide sales of Zetia, marketed as Ezetrol outside the U.S., were $560 million (-3%). Worldwide sales of Vytorin, marketed outside the U...